Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday.

According to Zacks, “Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered in Austin, United States. “

A number of other analysts also recently weighed in on the stock. ValuEngine downgraded shares of Threshold Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Ladenburg Thalmann Financial Services began coverage on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $0.40 target price on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $5.37.

Threshold Pharmaceuticals (MTEM) opened at 6.73 on Thursday. Threshold Pharmaceuticals has a one year low of $3.85 and a one year high of $14.52. The firm’s market capitalization is $180.91 million. The stock’s 50 day moving average is $5.63 and its 200-day moving average is $5.59.

Threshold Pharmaceuticals (NASDAQ:MTEM) last issued its quarterly earnings data on Monday, July 31st. The biotechnology company reported $0.22 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.99. The company had revenue of $3.00 million during the quarter. On average, analysts anticipate that Threshold Pharmaceuticals will post ($1.32) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Threshold Pharmaceuticals, Inc. (MTEM) Stock Rating Lowered by Zacks Investment Research” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/09/14/threshold-pharmaceuticals-inc-mtem-stock-rating-lowered-by-zacks-investment-research.html.

About Threshold Pharmaceuticals

Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

Receive News & Stock Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.